Global CRISPR And Cas Genes Market

The CRISPR and Cas Genes Market size was valued at USD 3.65 Billion in 2023 and the total CRISPR and Cas Genes revenue is expected to grow at a CAGR of 21.2% from 2024 to 2030, reaching nearly USD 14.05 Billion.

CRISPR And Cas Genes Market Overview:

CRISPR (clustered regularly interspaced short palindromic repeats) is a DNA sequence family found in the genomes of prokaryotic species like bacteria and archaea. During successive infections, they are employed to recognize and destroy DNA from related bacteriophages. During successive infections, they are employed to recognize and destroy DNA from related bacteriophages. As a result, these sequences play an important role in prokaryotes' antiviral (i.e. anti-phage) defensive system and provide a sort of acquired immunity. CRISPR is found in around half of all sequenced bacterial genomes and virtually all sequenced archaeal genomes.

Cas9 is an enzyme that recognizes and cleaves certain strands of DNA that are equivalent to the CRISPR sequence using CRISPR sequences as a guide. Cas9 enzymes and CRISPR sequences constitute the foundation of the CRISPR-Cas9 technology, which can be used to alter genes within organisms. This editing method offers a wide range of applications, including basic biology research, biotechnological product creation, and illness treatment.

To know about the Research Methodology :- Request Free Sample Report

CRISPR And Cas Genes Market Dynamics:

The market is being driven by the development of CRISPR-based diagnostic assays to overcome the timeline and sample collection issues for COVID-19 screening. High precision and sensitivity, accurate diagnosis, no need for specialized medical instruments, and portability are all features of the tests. For example, Gladstone Institutes researchers created a CRISPR-based test that uses cellphones to deliver results in December 2022. The Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer A. Doudna for their groundbreaking research on CRISPR/Cas9 genetic scissors for genome editing in 2022, which had a beneficial impact on the market.

Furthermore, the market is being driven by the development of CRISPR-based diagnostic assays to overcome the timeline and sample collection constraints for COVID-19 screening. High precision and sensitivity, rapid detection, no need for specialized laboratory equipment, and portability are all features of the tests. For example, Gladstone Institutes researchers created a CRISPR-based test that uses cellphones to deliver results in December 2022.

Likewise, the market is being driven by the development of CRISPR-based diagnostic assays to overcome the timeline and sample collection constraints for COVID-19 screening. High precision and sensitivity, rapid detection, no need for specialized medical instruments, and portability are all features of the tests. For example, Gladstone Institutes researchers created a CRISPR-based test that uses cellphones to deliver results in December 2022.

Key Development-

1. CRISPR Therapeutics and Vertex Pharmaceuticals, Inc. updated their collaboration agreement in April 2022, to develop CTX001, a CRISPR/Cas9-based gene editing therapeutic. This treatment can be used to treat sickle cell disease and transfusion-dependent beta-thalassemia (TDT) (SCD).

CRISPR And Cas Genes Market Segment Analysis:

The Product segment is leading the Application segment of the CRISPR And Cas Genes Market:

In 2021, the product sector dominated the market, accounting for 79.4 % of revenue. The increased demand for genome editing solutions is being met by the availability of novel tools and CRISPR gene editing kits for gene alteration investigations. Furthermore, the availability of improved individual products to serve many aims such as precise genome fragmentation, genome engineering, reduced off-target cutting, facile gene knockouts, and greater specificity supports the predicted market share.

Secondly, the market is likely to be driven by increased investments in gene editing-based R&D as well as the advent of fresh applications. For example, DNA-free Cas9 is likely to promote projected growth in the coming years, particularly in grapevine and apple protoplasts, rice lettuce, and tobacco.

The biomedical applications segment is dominating the Type segment of the CRISPR And Cas Genes Market:

In 2023, the biomedical applications category led the market, accounting for 92.8 % of revenue. The high income of this category is mostly due to the increasing use of CRISPR gene-editing techniques in a variety of biological fields. Throughout the forecast period, extensive biomedical research is expected to fuel the segment. Furthermore, the use of nano-carriers and the development of new delivery systems have greatly improved the efficacy and specificity of this technology. The CRISPR/Cas9 nuclease has made genome editing simple and precise. As a result, the use of CRISPR genome editing technology would be directly influenced by the field of gene and cell therapy.

The biotechnology and pharmaceutical companies’ segment is ruling the Type segment of the CRISPR and CAS Genes Market:

In 2023, the biotechnology and pharmaceutical businesses category led the market, accounting for 48.8% of total revenue. Pharmaceutical companies are increasingly turning to CRISPR-Cas9 to develop better biological models for human diseases in less time and to speed up the discovery and validation of new therapeutic targets. As a result, the development of a large clinical pipeline based on CRISPR gene-editing technology is projected to propel the industry forward. Furthermore, as cell and gene treatments gain traction, CRISPR-based gene-editing techniques are in high demand for the creation of innovative therapeutics. Contract research firms are likely to grow significantly in the predicted period as a result of this. Demand for CRISPR in this area is projected to be influenced by intense rivalry among companies with a focus on speed and cost reduction.

CRISPR And Cas Genes Market Regional Insights:

North America is estimated to dominate the growth of the CRISPR And Cas Genes Market.

North America dominated the CRISPR and Cas genes market in 2023, accounting for 38.4 % of total revenue. The region's supremacy has been aided by the region's expanding biopharmaceutical R&D, as well as the active involvement of numerous pharmaceutical companies in the creation of novel therapeutics through the use of genome editing tools. Furthermore, the United States has the most CRISPR papers in the region, indicating considerable study.

The market in the Asia Pacific is expected to develop at the fastest rate during the forecast period. This is due to the region's growing number of current clinical studies and increased research into gene-editing techniques. In addition, the rising popularity of CRISPR technology in Asian nations such as China and Japan is expected to boost the market's growth in the area.

The objective of the report is to present a comprehensive analysis of the CRISPR And Cas Genes Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the CRISPR And Cas Genes Market dynamics, structure by analyzing the market segments and projecting the CRISPR And Cas Genes Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the CRISPR And Cas Genes Market make the report investor’s guide.

CRISPR And Cas Genes Market Scope: Inquire before buying

CRISPR And Cas Genes Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

CRISPR And Cas Genes Market, Key Players

1. Astra Zeneca plc.
2. Addgene
3. Caribou Biosciences, Inc.
4. Cellectis, CRISPR Therapeutics
5. Editas Medicine, Inc.
6. eGenesis
7. F. Hoffmann-La Roche Ltd.
8. Horizon Discovery Group plc
9. GenScript
10.Danaher Corporation
11.Intellia Therapeutics, Inc.
12.Lonza
13.Merck KGaA
14.Intellia Therapeutics, Inc.
15.Takara Bio Inc.
16.Thermo Fisher Scientific, Inc.
17.Synthego
18.Mammoth Biosciences
19.Inscripta, Inc.
20.Cibus
21.Beam Therapeutics
22.PLANTeDIT
23.Vertex Pharmaceuticals Incorporated
24.Hera BioLabs
25.OriGene Technologies, Inc.
26.Recombinetics, Inc

FAQs:

1. What was the Global CRISPR and Cas Genes Market size in 2023?
Ans: The Global CRISPR and Cas Genes Market size was USD 3.65 Billion in 2023.

2. What are the CRISPR And Cas Genes Market growth?
Ans: The CRISPR And Cas Genes Market is anticipated to grow with a CAGR of 21.2% in the forecast period and is likely to reach USD 14.05 Billion by the end of 2030.

3. Which segment is expected to dominate the CRISPR And Cas Genes Market during the forecast period?
Ans: North America dominated the CRISPR And Cas Genes market with a share of 35.6% in 2019 owing to the increasing demand from the healthcare industry and growing awareness about workplace safety.

4. Who are the key players in the CRISPR And Cas Genes Market?
Ans: Some key players operating in the CRISPR and Cas genes market include AstraZeneca; Addgene; Caribou Biosciences, Inc.; Cellectis; Editas Medicine, Inc.; Egenesis; F. Hoffmann-La Roche Ltd.; Horizon Discovery Group Plc; Genscript; Danaher Corporation; Intellia Therapeutics, Inc.; Lonza; Merck KGaA; New England BioLabs; Takara Bio, Inc.; Synthego; Mammoth Biosciences; Inscripta, Inc.; and Cibus.

5. What is the key driving factor for the growth of the CRISPR And Cas Genes Market?
Ans: Key factors that are driving the CRISPR and Cas genes market growth include rising adoption in diverse fields of biotechnology, technological advancements in CRISPR, the introduction of anti-CRISPR protein, and ongoing competition for CRISPR commercialization.